UBS Evidence Lab Uses Hospital Data to Profile Regional Recoveries
The unit is combining foot-traffic data and proprietary datasets derived from hospitals to develop a better understanding of outbreaks and predict a timeline for recovery.
At the beginning of the pandemic, geolocation data played a key role in measuring the outbreak of the Covid-19 disease, and provided something of a warning system for firms as to where the next series of lockdowns were most likely to unfold.
While geolocation data is still being used to monitor for second- and third-wave outbreaks, it is also being used to highlight a return of business for regional hospitals, says Jeremy Brunelli, global head of frameworks at UBS Evidence Lab, the independent research unit separate from UBS Research.
The team is monitoring hospital admittance by measuring the foot traffic entering and leaving hospitals, looking at factors such as inpatient and outpatient volumes, emergency room numbers, total surgeries, and elective procedures. It is partnering with an undisclosed data vendor that cleanses and anonymizes the hospital traffic dataset.
“This is an exclusive dataset that we have, and we get about two reads every month. We have an initial read, which is not the full sample, but it gives us an early indication, and then we get a final read at the end of the month. This is a dataset where we can see a dramatic decline in the volumes [of elective procedures and surgeries] driven by Covid-19,” he says.
So, for example, in Washington State, which was the first epicenter of the coronavirus in the US, hospital admittance data showed a significant drop in the number of non-emergency procedures back at the beginning of the pandemic, but those numbers are now improving. In April, there was a 70% year-on-year decline in non-emergency medical procedures, May saw a 50% decline compared to the previous May, June saw a still robust 22% decline, but July saw only a 7% decline, according to Brunelli.
The Evidence Lab uses the Bayesian inference approach to combine multiple datasets to see if they support or disprove a probable investment hypothesis. This is where alternative datasets on health care can be valuable, says Brunelli, as they can more accurately reflect world events than traditional market data.
“We would create this big mosaic of datasets and try to present it in a very digestible way for investors, so that they can look across this mosaic and start to increase or decrease their confidence around some hypothesis they have,” he says.
To supplement the hospital admittance data, UBS also conducts a proprietary survey, called a pulse check. The survey puts questions to 40 different C-level hospital executives in the US to learn about the current conditions, in terms of surgery procedures and capital expenditure plans, including funding spent on technologies and beds. Brunelli says that the two data products—the foot traffic and the survey—provide complimentary views on the events unfolding in hospitals
“There are still a significant amount of delays, but they’ve also improved as things have reopened and recovered, especially with orthopedic surgeries—we’ve seen 43% of hospitals are reporting delays versus 58% in May, and plastic surgeries and endoscopies have also seen a decrease in delays,” he adds.
Yet, these various healthcare insights are not used in isolation. Brunelli says they are most effective when used to compliment other foot traffic or mobility datasets that look at activity around retail shopping, public transit usage, and car traffic congestion, to help understand the pace of recovery in different locations.
For example, mobile device application publishers use Google’s software development kit and tie it to Google Maps, and embed it into their own technology frameworks. The location data of the person using the app is then pulled, aggregated, anonymized, and then sold to users like UBS, and they can more accurately see spikes in traffic or activity around retail centers. The Evidence Lab also takes in satellite data from location, navigation, and map technology provider TomTom to monitor auto congestion, and combines that with metrics on app usage from Sensor Tower, which provides data around mobile app usage.
“We use hundreds of vendors and also have, what we call, an internal harvest team,” Brunelli says, “where we web-mine thousands of different types of data from the internet, which we curate and create metrics with.”
Further reading
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe
You are currently unable to print this content. Please contact info@waterstechnology.com to find out more.
You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.
Copyright Infopro Digital Limited. All rights reserved.
As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (point 2.4), printing is limited to a single copy.
If you would like to purchase additional rights please email info@waterstechnology.com
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (clause 2.4), an Authorised User may only make one copy of the materials for their own personal use. You must also comply with the restrictions in clause 2.5.
If you would like to purchase additional rights please email info@waterstechnology.com
More on Data Management
New working group to create open framework for managing rising market data costs
Substantive Research is putting together a working group of market data-consuming firms with the aim of crafting quantitative metrics for market data cost avoidance.
Off-channel messaging (and regulators) still a massive headache for banks
Waters Wrap: Anthony wonders why US regulators are waging a war using fines, while European regulators have chosen a less draconian path.
Back to basics: Data management woes continue for the buy side
Data management platform Fencore helps investment managers resolve symptoms of not having a central data layer.
‘Feature, not a bug’: Bloomberg makes the case for Figi
Bloomberg created the Figi identifier, but ceded all its rights to the Object Management Group 10 years ago. Here, Bloomberg’s Richard Robinson and Steve Meizanis write to dispel what they believe to be misconceptions about Figi and the FDTA.
SS&C builds data mesh to unite acquired platforms
The vendor is using GenAI and APIs as part of the ongoing project.
Aussie asset managers struggle to meet ‘bank-like’ collateral, margin obligations
New margin and collateral requirements imposed by UMR and its regulator, Apra, are forcing buy-side firms to find tools to help.
Where have all the exchange platform providers gone?
The IMD Wrap: Running an exchange is a profitable business. The margins on market data sales alone can be staggering. And since every exchange needs a reliable and efficient exchange technology stack, Max asks why more vendors aren’t diving into this space.
Reading the bones: Citi, BNY, Morgan Stanley invest in AI, alt data, & private markets
Investment arms at large US banks are taken with emerging technologies such as generative AI, alternative and unstructured data, and private markets as they look to partner with, acquire, and invest in leading startups.